Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation

Area of Science:

• Immunology
• Biochemistry
• Drug Discovery

Background:

• Leukocyte adherence via ICAM-1/LFA-1 binding is vital for immune and inflammatory functions.
• Inhibiting ICAM-1/LFA-1 interactions shows therapeutic potential in lymphoma and inflammatory diseases like arthritis and septic shock.

Purpose of the Study:

• To develop and characterize a small peptide antagonist targeting ICAM-1-dependent cell aggregation.
• To identify a novel molecule for studying ICAM-1 biology and developing therapeutics.

Main Methods:

• Utilized phage display technology with a cyclic nonapeptide library to select for ICAM-1 binding peptides.
• Synthesized and tested cyclic and linear IP01 peptides for their ability to inhibit ICAM-1-mediated cell aggregation.
• Performed alanine scanning mutagenesis to identify key amino acids in IP01 responsible for inhibition.
• Assessed IP01's effect on neutrophil adhesion under physiologic flow conditions.

Main Results:

• Identified and selected the cyclic nonapeptide IP01 (C*LLRMRSIC*) for its potent inhibition of ICAM-1-dependent cell aggregation.
• Cyclic and linear IP01 peptides inhibited ICAM-1-mediated aggregation at 1 mM, with cyclic IP01 showing an IC50 of ~970 µM.
• IP01 did not affect aggregation mediated by ICAM-2 or ICAM-3, indicating specificity.
• Key inhibitory residues in cyclic IP01 were identified as leucine 2, leucine 3, methionine 5, and arginine 6.
• Cyclic IP01 effectively inhibited neutrophil firm adhesion to endothelium in a flow assay.

Conclusions:

• A novel small peptide, cyclic IP01, was developed that specifically inhibits ICAM-1-dependent cell adhesion.
• IP01's mechanism of action is distinct from LFA-1, offering a unique therapeutic target.
• IP01 serves as a valuable tool for investigating ICAM-1/LFA-1 biology and as a lead for small molecule drug development.